Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.00    -0.60 (-0.38%)
Bid:
156.40
Ask:
156.80
Spread: 0.40 (0.256%)
Market Cap: £891.97m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Directorate Change

23 Feb 2017 09:00

ELEMENTIS PLC - Directorate Change

ELEMENTIS PLC - Directorate Change

PR Newswire

London, February 23

23 February 2017

Elementis – Directorate Changes

Elementis plc (ELM.L) (the “Company”), the FTSE 250 Global Specialty Chemicals Company, today announces the following changes to its Board of Directors (“Board”).Change of responsibilitiesAndrew Christie, who will complete 9 years on the Board this Summer and who has been Chairman of the Remuneration Committee since October 2013, will be stepping down from this role and as a non-executive Director following the conclusion of the Annual General Meeting to be held on 25 April 2017.Steve Good who has been a non-executive Director since October 2014 will become Chairman of the Remuneration Committee on 26 April 2017.Andrew Duff, Chairman of Elementis, said: “On behalf of the Board, I would like to thank Andrew for his significant contribution to the Company’s success over the past 9 years, particularly as Chairman of the Remuneration Committee where a lot of progress has been made to update our policies in line with market practice. His corporate finance expertise and strategic insights have also been very valuable to us. I wish him well in his future endeavours.”Appointment of additional non-executive DirectorFollowing a review of its structure, the Board has decided to increase its size from 7 to 8 members to broaden its international profile and expertise and to improve resilience by appointing Dorothee Deuring as a non-executive Director with effect from 1 March 2017. She will be a member of the Nomination, Audit and Remuneration Committees.Dorothee Deuring is a non-executive director of Bilfinger SE, a German listed industrial services provider (where she is also a member of its audit committee), and Röchling Group SE, a privately owned group processing engineering plastics (both since 2016), as well as managing her own corporate advisory consultancy serving a number of European clients in the pharma/biotech sector. Her previous executive roles included managing director and head of Corporate Advisory Group (Europe) at UBS in Zurich, head of M&A chemicals and healthcare at a private investment bank in Germany and as a senior executive in the corporate finance department at the Roche group.Dorothee is an Austrian national and has an MSc. degree in Chemistry from the Université Louis Pasteur, Strasbourg, and an MBA from INSEAD.Andrew Duff, Chairman of Elementis, said: “Dorothee is an excellent addition to the Board and her experience and background will bring new skills and insights into our boardroom. I am confident that with her corporate finance expertise and broader chemicals sector knowledge, she will make a positive contribution to the Board’s performance and the quality of its discussions.”The Company confirms that there are no other matters requiring disclosure in relation to listing rule 9.6.13.Changes in membership of Board CommitteesFollowing the appointments of Sandra Boss and Dorothee Deuring this year, the Board has carried out a review of the structure and composition of its Committees and decided to make a number of changes as set out below. These changes will be effective from 26 April 2017:

Anne Hyland, who is Chairman of the Audit Committee and a member of the Remuneration and Nomination Committees, will be standing down as a member of the Remuneration Committee.

Steve Good, who will become Chairman of the Remuneration Committee on 26 April 2017 and is also a member of the Audit and Nomination Committees, will be standing down as a member of the Audit Committee.The membership of the Board’s Committees on 26 April 2017 will be as follows:Audit CommitteeAnne Hyland (Chair), Sandra Boss, Dorothee Deuring and Nick Salmon.Remuneration CommitteeSteve Good (Chair), Sandra Boss, Dorothee Deuring and Nick Salmon.Nomination CommitteeAndrew Duff (Chair), Sandra Boss, Dorothee Deuring, Steve Good, Anne Hyland and Nick Salmon.Wai WongCompany Secretary020 7067 2999

Date   Source Headline
21st Jan 20257:00 amRNSTrading Update
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.